Trial · NCT04976478
Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
NCT04976478, Not yet recruiting, Peking University Third Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma. Trials, record NCT04976478. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04976478
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
- NCT number
- NCT04976478
- Status
- Not yet recruiting
- Enrollment
- 125 participants, estimated
- Lead sponsor
- Peking University Third Hospital
- Conditions
- Cervical Squamous Cell Carcinoma
- Interventions
- Nimotuzumab, EBRT combined with brachytherapy
- First posted
- 2021-07-26
- Last updated
- 2021-07-26
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-year disease-free survival(DFS) | up to 3 years | The rate of patient without disease in 3 years after treatment |
| Secondary | Complete response rate(CRR) | 3 months later after treatment | The percentage of subjects who achieve complete response by imaging assessment from the end of the treatment to disease progression |
| Secondary | Objective response rate(ORR) | 3 months later treatment | The percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment |
| Secondary | 3-year overall survival(OS) | up to 3 years | The rate of patient alive in 3 years after treatment |
| Secondary | The change of tumor related markers | up to 3 years | the correlation of the value of SCC，Cyfra 21-1 and therapeutic effect \[The changes of serum tumor markers (such as SCC-Ag and CYFRA21-1) were observed before and after treatment\] |
| Secondary | The change of cervical tumor | At diagnosis and before brachytherapy | the change of the volume of the cervical tumor at diagnosis and before brachytherapy |
| Secondary | QUALITY OF LIFE(QoL) | up to 3 years | Quality of life assessed by EORTC QLQ-CX 24 \[EORTC QLQ-CX 24 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 24 items\] |
| Secondary | SAFETY | up to 3 years | Including severity of adverse events, the incidence of adverse events and serious adverse events. Adverse events should be reported and graded according to CTCAE version 5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04976478
GET https://conductscience.org/api/trials/v1/NCT04976478/registered